Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib [4]

American Journal of Medicine

Volumn 115, Issue 7, 2003, Pages 587-589

  Koury, Mark J ^a   Newman, John H ^a   Murray, John J ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HYDROXYUREA; IMATINIB; INTERLEUKIN 5; MEPOLIZUMAB; METHOTREXATE; PREDNISONE; PROTEIN TYROSINE KINASE; PSORALEN;

ADULT; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; HEART VENTRICLE FAILURE; HUMAN; HYPEREOSINOPHILIC SYNDROME; LETTER; LEUKOCYTE COUNT; LYMPHOMATOID PAPULOSIS; MALE; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION;

EID: 0242361303     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(03)00475-3     Document Type: Letter

References (9)

1. Rothenberg M.E. Mechanisms of disease eosinophilia . N Engl J Med. 338:1998;1592-1597.
2. Simon H.U., Plotz S.G., Dummer R., et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 341:1999;1112-1120.
3. Whittaker S.J., Jones R.R., Spry C.J.F. Lymphomatoid papulosis and its relationship to "idiopathic" hypereosinophilic syndrome. J Am Acad Dermatol. 18:1998;339-344.
4. Granel B., Serratrice J., Swiader L., et al. Lymphomatoid papulosis associated with both the severe hypereosinophilic syndrome and CD30 positive large T-cell lymphoma. Cancer. 89:2000;2138-2142.
5. Savage D.G., Antman K.H. Imatinib mesylate - a new oral targeted therapy. N Engl J Med. 346:2002;683-693.
6. Gleich G.J., Leiferman K.M., Pardanani A., et al. Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet. 359:2002;1577-1578.
7. Pardanani A.D., Reeder T.L., Porrata L.F., et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 101:2003;3391-3397.
8. Cortes J., Ault P., Koller C., et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 101:2003;4714-4716.
9. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 348:2003;1201-1214.